Key facts
as of Sep 2026- Antares Therapeutics’s last known valuation is $299.0M (Apr 2025).
- It has raised $177.0M across 2 recorded rounds; the latest was Early Stage VC ($30.0M) in May 2025.
- Notable investors include Lightspeed Venture Partners, Cormorant Asset Management, Invus Opportunities, Omega Funds, Atlas Venture — 11 tracked in total.
- 1 institutional filer reports fund marks on Antares Therapeutics across 5 filings.
- Antares Therapeutics has filed 2 Form Ds with the SEC, most recently May 2025 ($30.0M sold to 35 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Antares Therapeutics
Recorded secondary trades
No secondary trades in Antares Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 5 fair-value marks on Antares Therapeutics between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAbout Antares Therapeutics
Operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets. The company offers an integrated drug discovery platform combining advanced computational chemistry, predictive sciences and experimental biology, enabling the development of transformative therapies for patients with high unmet medical needs.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Employees
- 100
- Website
- antaresrx.com/
- Ownership
- Privately Held (backing)